Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
Inhibitors of VEGF (vascular endothelial growth factor)/VEGFR2 (vascular endothelial growth
factor receptor 2) are commonly used in the clinic, but their beneficial effects are only …
factor receptor 2) are commonly used in the clinic, but their beneficial effects are only …
[HTML][HTML] Augmenting anticancer immunity through combined targeting of angiogenic and PD-1/PD-L1 pathways: challenges and opportunities
SP Hack, AX Zhu, Y Wang - Frontiers in Immunology, 2020 - frontiersin.org
Cancer immunotherapy (CIT) with antibodies targeting the programmed cell death 1 protein
(PD-1)/programmed cell death 1 ligand 1 (PD-L1) axis have changed the standard of care in …
(PD-1)/programmed cell death 1 ligand 1 (PD-L1) axis have changed the standard of care in …
Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade
M Schmittnaegel, N Rigamonti, E Kadioglu… - Science translational …, 2017 - science.org
Pathological angiogenesis is a hallmark of cancer and a therapeutic target. Vascular
endothelial growth factor A (VEGFA) and angiopoietin-2 (ANGPT2; also known as ANG2) …
endothelial growth factor A (VEGFA) and angiopoietin-2 (ANGPT2; also known as ANG2) …
Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models
Q Wang, J Gao, W Di, X Wu - Cancer Immunology, Immunotherapy, 2020 - Springer
The effectual clinical benefits of immune checkpoint inhibitor (ICI) are hampered by a high
rate of innate resistance, and VEGFA may contribute to ICI treatment resistance. In this study …
rate of innate resistance, and VEGFA may contribute to ICI treatment resistance. In this study …
[HTML][HTML] Direct and indirect modulation of T cells by VEGF-A counteracted by anti-angiogenic treatment
M Bourhis, J Palle, I Galy-Fauroux… - Frontiers in immunology, 2021 - frontiersin.org
Vascular endothelial growth factor A is known to play a central role in tumor angiogenesis.
Several studies showed that VEGF-A is also an immunosuppressive factor. In tumor-bearing …
Several studies showed that VEGF-A is also an immunosuppressive factor. In tumor-bearing …
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
D Fukumura, J Kloepper, Z Amoozgar… - Nature reviews Clinical …, 2018 - nature.com
Immunotherapy has emerged as a major therapeutic modality in oncology. Currently,
however, the majority of patients with cancer do not derive benefit from these treatments …
however, the majority of patients with cancer do not derive benefit from these treatments …
[HTML][HTML] Old player-new tricks: non angiogenic effects of the VEGF/VEGFR pathway in cancer
P Ntellas, L Mavroeidis, S Gkoura, I Gazouli, AL Amylidi… - Cancers, 2020 - mdpi.com
Simple Summary Although VEGF-A is well characterized as the principal player of cancer
angiogenesis, new data on the interplay with other components of the tumor …
angiogenesis, new data on the interplay with other components of the tumor …
[HTML][HTML] Combining immune checkpoint inhibitors with anti-angiogenic agents
P Ciciola, P Cascetta, C Bianco, L Formisano… - Journal of clinical …, 2020 - mdpi.com
Immunotherapy has recently emerged as a novel strategy for treating different types of solid
tumors, with promising results. However, still a large fraction of patients do not primarily …
tumors, with promising results. However, still a large fraction of patients do not primarily …
Direct and indirect regulation of the tumor immune microenvironment by VEGF
Y Zhang, RA Brekken - Journal of leukocyte biology, 2022 - academic.oup.com
Vascular endothelial growth factor-A (VEGF) is the predominant angiogenic factor that is
expressed in solid tumors. Besides its critical function in mediating tumor angiogenesis …
expressed in solid tumors. Besides its critical function in mediating tumor angiogenesis …
Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
PS Hegde, JJ Wallin, C Mancao - Seminars in cancer biology, 2018 - Elsevier
The critical role of angiogenesis in promoting tumor growth and metastasis has been well
established scientifically, and consequently blocking this pathway as a therapeutic strategy …
established scientifically, and consequently blocking this pathway as a therapeutic strategy …